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Life is the integration of numerous chemical interactions conducted by low molecular weight compounds and proteins. 
Our interest is understanding the mechanisms of these interactions from the viewpoint of  organic chemistry. Our current 
research focuses on the following: a) Design and synthesis of a series of chemical probes in order to reveal not only 
ligand–protein and protein–protein interactions, but also behavior of low molecular weight compounds per se. b) Un-
raveling biosynthetic pathways of bioactive natural products at enzyme level. c) Application of our chemical probes in devel-
opment of novel practical bioactive compounds.
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Determination of a Key Residue of γ-Glutamyl 
Transpeptidase for Substrate Recognition
γ-Glutamyl transpeptidase (GGT) plays a central role in 
homeostasis of antioxidant tripeptide glutathione, and has 
been implicated in a vast array of physiological disorders. 
In this study, we synthesized a series of mechanism-based 
GGT inhibitors to probe electrostatic interactions between 
the acceptor site residues of GGT and substrates. Our 
chemical, enzymological, and molecular biological ap­
proaches revealed that 3-hydroxyphenylacetic acid is an 
excellent mimic of the cysteinylglycine moiety of glutathi­
one, and Lys562 of human GGT strongly recognizes their 
negative charge on the carboxy group (Figure 1). We 
demonstrated that this interaction considerably enhances 
the human GGT specificity of our inhibitor named GGsTop. 
GGsTop exhibited no inhibitory activity at 10 mM on a 
representative member of glutamine-dependent amido­
transferases essential for a wide range of biosynthetic path­
way, and showed no cytotoxicity toward human fibroblasts 
and hepatic stellate cells up to 1 mM.
Substrate-Analog Fructosyl Peptide Oxidase 
Inhibitors
Fructosyl peptide oxidase (FPOX) is widely used in the 
area of diabetes diagnosis today. In this study, we designed 
and synthesized its substrate-analog inhibitors in order to 
unveil the substrate recognition mechanism of FPOX by 
X-ray diffraction analysis of enzyme-inhibitor co-crystals. 
Kinetic study revealed that our substrate analogs act as 
competitive inhibitors with Ki values ranging from 11.1 to 
782 µM (Figure 2). Co-crystallization of the enzyme with 
our inhibitors in order to determine the three­dimensional 
structure of FPOX is now in progress.
Molecular Mechanism of Myocardin-Related 
Transcription Factor A Inhibitors
Myocardin-related transcription factor A (MRTF-A) 
plays a pivotal role in epidermal-msenchymal transition. 
Inhibition of its nuclear transport is regarded as one of the 
attractive therapeutic targets since MRTF-A is closely as­
sociated with cancer and tissue fibrosis. In this study, we 
revealed that CCG-1423, originally developed as a Rho 
inhibitor, binds to the nuclear localization signal of 
MRTF-A and inhibits its nuclear transport mediated by im­
portin-α/β1 (Figure 3). We also demonstrated that CCG-
1423 inhibits a migration of melanoma cells triggered by 
MRTF-A activation, and the potency is affected by the 
stereochemistry of CCG-1423. The difference is elucidated 
by the binding manner of each stereoisomer to MRTF-A 
that speculated by a molecular modeling approach.
Figure 1. Proposed binding mode of GGsTop, glutathi­
one, and acceptor substrate (Gly-Gly) to Lys562.
Figure 2. Chemical structures and inhibitory 
activity of FPOX inhibitors.
Figure 3. Molecular mechanism of MRTF-A 
inhibitor CCG-1423.
